Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Get your full text copy in PDF

Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)

Dinah V. Parums

(Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA)

Med Sci Monit 2021; 27:e932899

DOI: 10.12659/MSM.932899

ABSTRACT: During 2020 and 2021, the global pandemic of coronavirus disease 2019 (COVID-19) due to severe acute respi- ratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in high death rates and acute and chronic morbidity in all countries. The rapid development of new mRNA vaccines to SARS-CoV-2 brings hope that the spread of this virus can be controlled. The ChAdOx1 nCoV-19 vaccine developed by a collaboration between the University of Oxford and AstraZeneca showed efficacy in clinical trials, with a good safety profile. However, there have been recent reports of the rare development of thrombotic events in young women following vaccination with ChAdOx1 nCoV-19, particularly of the rare condition of cavernous sinus thrombosis. Studies have begun to in- vestigate whether antibodies to the SARS-CoV-2 spike cross-react with platelet factor 4 (PF4/CXLC4) and mim- ic autoimmune heparin-induced thrombocytopenia. This Medical Science Monitor Editorial aims to briefly update the current status of studies on a possible rare complication of using new mRNA vaccines to prevent COVID-19.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree